Upper respiratory tract is equipped with several host-defense mechanisms in order to protect the host against continuous invasion by microorganisms and allergens.Secretory IgA is the chief agent of mucosal immune system and excludes microorganisms by agglutination without destroying them. Nasal associated lymphoid tissue (NALT) acts as an inductive site to induce secretory IgA in upper respiratory tract and has different organogenesis from the other inductive sites. Recent studies demonstrated that CD3
-CD4
+CD45
+cells, Id2 gene, and CXCL13, are essential to construct NALT. Not only the mechanisms in inducing mucosal immune responses in upper respiratory tract, but also the usefulness of intra-nasal vaccination has been attracted. Intra-nasal immunization of mice with pneumococcal surface protein A (PspA) of
Streptococcus pneumoniaeand outer membrane protein P6 of
Haemophilus influenzaeenhanced the clearance of those bacteria from nasal and middle ear cavities. Moreover, intra-nasal immunization with phosphorylcholine (PC) elicited protective mucosal immunity against most different strains of S.
pneumoniaeand
H. influenzae, indicating that PC might be a promising wide spectrum vaccine. Since mucosal immune responses are associated with type I allergy mediated by IgE, mucosal vaccine might be effective to prevent nasal allergy. In facts, intra-nasal immunization with ovalbumin induced mucosal immune tolerance. Further, clinical trials have demonstrated that sublingual immunization with pollen extracts improved nasal symptoms and medication scores. Those finding suggest that mucosal vaccination can be applied for preventing upper respiratory infections and for the treatment of nasal allergy.
View full abstract